141 related articles for article (PubMed ID: 38584883)
1. Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age.
Armstrong A; Ho H; Mark Tacey M; Bolton D; Chan Y; Tan A; Cham CW; Pham T; McMillan K; Koufogiannis G; Dip G; Manohar P; Guerrieri M; Ng M; Joon DL; Foroudi F; Tan MY; Chao M
J Contemp Brachytherapy; 2024 Feb; 16(1):6-11. PubMed ID: 38584883
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer.
Ueno Y; Fukumori T; Kusuhara Y; Fukawa T; Tsuda M; Daizumoto K; Sasaki Y; Tomida R; Yamamoto Y; Yamaguchi K; Tonoiso C; Kubo A; Kawanaka T; Furutani S; Ikushima H; Takahashi M; Kanayama HO
In Vivo; 2023; 37(2):738-746. PubMed ID: 36881090
[TBL] [Abstract][Full Text] [Related]
4. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study.
Reynaud T; Hathout L; Carignan D; Barkati M; Martin AG; Foster W; Lacroix F; Delouya G; Taussky D; Morton G; Vigneault E
Brachytherapy; 2021; 20(6):1090-1098. PubMed ID: 34238688
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
6. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
8. A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.
Chao M; Spencer S; Guerrieri M; Ding W; Goharian M; Ho H; Ng M; Healey D; Tan A; Cham C; Joon DL; Lawrentschuk N; Travis D; Sengupta S; Chan Y; Troy A; Pham T; Clarke D; Liodakis P; Bolton D
J Contemp Brachytherapy; 2018 Apr; 10(2):155-161. PubMed ID: 29789764
[TBL] [Abstract][Full Text] [Related]
9. Defining Biochemical Cure After Low Dose Rate Prostate Brachytherapy: External Validation of 4-year Prostate-specific Antigen Nadir as a Predictor of 10- and 15-year Disease-free Survival.
Noble DJ; Doyle E; Tramonti G; Law AB; Sundaramurthy A; Brush JP; Keanie J; Wood C; Drewell P; Keough W; McLaren DB
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):42-49. PubMed ID: 34848134
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
12. Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.
Anderson E; Smyth LML; O'Sullivan R; Ryan A; Lawrentschuk N; Grummet J; See AW
Transl Androl Urol; 2021 Sep; 10(9):3591-3603. PubMed ID: 34733655
[TBL] [Abstract][Full Text] [Related]
13. Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer.
Chao M; Joon DL; Khoo V; Spencer S; Ho H; Guerrieri M; Foroudi F; Bolton D
J Med Imaging Radiat Sci; 2019 Mar; 50(1):82-86. PubMed ID: 30777253
[TBL] [Abstract][Full Text] [Related]
14. Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer.
Kunogi H; Wakumoto Y; Kawamoto T; Oshima M; Horie S; Sasai K
J Contemp Brachytherapy; 2020 Dec; 12(6):554-561. PubMed ID: 33437303
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
Urabe F; Miki K; Kimura T; Sasaki H; Tashiro K; Iwatani K; Matsukawa A; Aikawa K; Tsusumi Y; Morikawa M; Minato K; Sato S; Takahashi H; Aoki M; Egawa S
Prostate; 2023 Feb; 83(2):135-141. PubMed ID: 36176043
[TBL] [Abstract][Full Text] [Related]
16. Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.
Moran BJ; Rice SR; Chhabra AM; Amin N; Braccioforte M; Agarwal M
Brachytherapy; 2019; 18(6):800-805. PubMed ID: 31427178
[TBL] [Abstract][Full Text] [Related]
17. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
18. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
19. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
20. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
